Curosurf

Curosurf (Poractant Alfa) is a surfactant replacement therapy used to treat respiratory distress in premature infants. This product helps improve lung function and oxygenation, often administered via endotracheal tube.

Curosurf is primarily used to treat respiratory distress syndrome (RDS) in premature infants. This condition occurs when the lungs are not fully developed and lack sufficient surfactant, a substance that keeps the air sacs open. Curosurf works by replacing this missing surfactant, allowing the lungs to function more effectively. It is typically administered directly into the lungs via an endotracheal tube.

Curosurf helps to reduce the surface tension in the lungs, which can improve oxygenation and lung compliance. This can lead to better breathing and reduced need for mechanical ventilation in premature infants. The effects are generally observed shortly after administration.

Curosurf should be used under the supervision of a healthcare professional. It is important to follow proper administration techniques to ensure effective delivery and minimize the risk of complications. Always store Curosurf according to the manufacturer's instructions to maintain its efficacy.

Curosurf is generally well-tolerated, but it is important to inform your healthcare provider about any other medications or treatments your infant is receiving. This can help avoid potential interactions and ensure the safe use of Curosurf.